MADISON, Wis.--(BUSINESS WIRE)--The most commonly diagnosed form of childhood leukemia, acute lymphoblastic leukemia (ALL), often responds well to biologically-targeted therapeutic treatments, but also carries a 25% risk for relapse. ALL is frequently associated with a chromosomal translocation that involves the specific translocation of gene loci from the short (p) arm of chromosome 12 to chromosome 21 denoted as t(12;21) TEL-AML1 (ETV6-RUNX1). This translocation often results in fusions of the TEL (or ETV6) gene with the AML1 (or RUNX1) gene and is present in 1% of all newborns and at a higher 22% proportion among children with the ALL diagnosis.
